Syra Health Delivers Third Consecutive Profitable Quarter: Record Revenue of $2.6 Million, Up 52%, and 46.3% Gross Margin

• Revenue climbed 52% year-over-year to $2.6 million in Q3 2026, the highest quarterly revenue in the Company's history.
• Earnings per share (EPS) swung to $0.02 in Q3 2026, compared with a loss of $(0.02) in Q3 2025.
• Gross margin reached a Company record of 46.3% in Q3 2026, up 1,340 basis points from 32.9% in Q3 2025.
• EBITDA turned positive at $301,725 in Q3 2026, a $520,326 improvement from a loss of $(218,601) in Q3 2025.

CARMEL, Ind., Nov. 3, 2026 — Syra Health Corp. (OTCQB: SYRA) ("Syra Health" or the "Company"), an integrated healthcare solutions company powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today its financial results for the third quarter ended September 30, 2026.

Q3 2026 Financial Highlights

"Syra Health Delivers Third Consecutive Profitable Quarter: Record Revenue of $2.6 Million and 46.3% Gross Margin"

Post this

Syra Health extended its profitability in Q3 2026, reporting net income of $344,610 compared with a net loss of $(225,902) in Q3 2025, a year-over-year improvement of $570,512.

Revenue for the quarter ended September 30, 2026, climbed 52% to a record $2.6 million, the highest quarterly revenue in the Company's history, up from $1.7 million in the prior-year period.

With revenue growing faster than costs, gross margin widened by approximately 1,340 basis points to 46.3%, up from 32.9% a year earlier. The result sets a new Company record, surpassing the previous high of 44.5% achieved just last quarter.

EPS rose to $0.02 from a loss of $(0.02) in Q3 2025, a year-over-year improvement of $0.04 per share.

EBITDA improved by $520,326 or 238.03% to $301,725 in Q3 2026, compared with a loss of $(218,601) in Q3 2025.

Year-to-date results reinforce the strength of the business. For the nine months ended September 30, 2026, Syra Health generated net income of $ 835,831 compared with a net loss of $(761,763) a year earlier, while net cash provided by operating activities reached $975,023, compared with net cash used in operating activities of $(158,554) in the prior-year period.

2026 Financial Outlook

With three consecutive profitable quarters now behind us, Syra Health remains on track to achieve its previously stated goal of full-year profitability in 2026. Given the RFP- and contract-driven nature of its business, the Company continues to expect the timing of awards, revenue recognition, and contract milestones to cause some quarter-to-quarter variability.

Recent Operational Highlights

• Syra Health continues to grow its work with managed care organizations (MCOs) serving hundreds of thousands of Medicaid members, including large-scale engagements that span:
  • Population health implementations that collect, analyze, and report on claims data
  • A live-agent call center focused on improving quality measures and closing care gaps
  • Process design for expedited credentialing and recredentialing of Medicaid providers
  • Staffing of utilization management nurses
• Following CMS approval of Syrenity for the ACCESS Model, Syra Health is actively recruiting Accountable Care Organizations (ACOs) to utilize Syrenity, delivered with partner HealthSync, as part of their participation in the model.

Management Commentary

Greg Alexander, CEO of Syra Health, said, "Q3 2026 marks our third consecutive profitable quarter, and it is the clearest evidence yet that Syra Health has become a profitable growth company. We grew revenue 52% year-over-year to a record $2.6 million, and we did it profitably: gross margin reached 46.3%, the highest in our history, up more than 13 percentage points from a year ago. That kind of growth paired with that kind of margin expansion doesn't happen by accident. It reflects deliberate choices we have made to focus on our high-value population health solutions, pursue better-margin workforce contracts, and run the business with discipline.

The results speak to the durability of what we're building. Through the first nine months of 2026, we generated net income of $835,831 compared with a loss of $(761,763) in the same period last year, produced $975,023 in operating cash flow, and ended the quarter with $2.4 million in cash and no long-term debt. We are funding our own growth, including continued investment in Syrenity Enterprise, our B2B mental and behavioral health solution.

We believe the best is still ahead. Our approval for Syrenity within the CMS ACCESS Model with our partner HealthSync is expected to become a consistent source of revenue over the next decade. With strong momentum across our business, we remain focused on delivering full-year profitability in 2026 and creating long-term value for our customers, the communities we serve, and our shareholders."

Q3 2026 Financial Results

Third quarter 2026 revenue rose 52% to $2,557,295, up from $1,687,971 in the third quarter of 2025. The Company's high-margin population health solutions continued to lead the way, also growing 52% year-over-year to $1,943,788 from $1,280,011 in the same period of 2025.

Healthcare workforce revenue increased 50% to $613,507 from $407,960 a year earlier as Syra Health met rising demand for solutions that address critical healthcare workforce shortages while prioritizing contracts with stronger margins.

Gross profit margin widened by 1,340 basis points to 46.3% in the third quarter of 2026, up from 32.9% in the prior year period, driven by a favorable revenue mix and ongoing operating leverage.

The Company balanced disciplined cost management with targeted investment in growth. Salaries and benefits grew to $440,172 in Q3 2026 from $336,390 in the prior-year period as Syra Health added talent to support its expansion. Professional services fell 9% to $175,295 in Q3 2026 from $191,726 in Q3 2025, and selling, general and administrative expenses declined 12% to $222,141 from $252,384 in the prior-year period. Research and development expenses increased to $46,716 in Q3 2026 from $816 in Q3 2025, funding the build-out of Syrenity Enterprise, the Company's B2B mental and behavioral health solution. Depreciation expense dropped 87% to $715 from $5,396 a year earlier.

Operating activities provided $975,023, in net cash for the nine months ended September 30, 2026 compared with $(158,554) in the prior-year period. Cash and cash equivalents grew to $2.4 million as of September 30, 2026, from $1.6 million as of December 31, 2025, with no long-term debt.

SYRA HEALTH CORP. BALANCE SHEETS
		September 30,				December 31,
		2026				2025
		(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents		$	2,383,413			$	1,614,733
Accounts receivable, net			1,517,493				918,374
Other current assets			262,998				205,423
Total current assets			4,163,904				2,738,530
Property and equipment, net			4,476				6,986
Right-of-use asset			57,010				27,401
Total assets		$	4,225,390			$	2,772,917
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable		$	211,169			$	247,520
Accounts payable, related party			125,000				72,000
Accrued expenses			367,996				194,821
Deferred revenue			261,249				16,611
Current portion of operating lease liability, related party			57,010				27,401
Notes payable			179,272				116,386
Total current liabilities			1,201,696				674,739
Non-current portion of operating lease liability, related party			-				-
Total liabilities			1,201,696				674,739
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares designated, issued and outstanding			-				-
Class A common stock, $0.001 par value, 100,000,000 shares authorized, 13,850,279 and 11,339,169 shares issued and outstanding, respectively			13,850				11,339
Convertible class B common stock, $0.001 par value, 5,000,000 shares authorized, 350,000 and 600,000 shares issued and outstanding, respectively			350				600
Additional paid-in capital			11,894,189				11,806,765
Accumulated deficit			(8,884,695)				(9,720,526)
Total stockholders' equity			3,023,694				2,098,178
Total liabilities and stockholders' equity		$	4,225,390			$	2,772,917

SYRA HEALTH CORP. STATEMENTS OF OPERATIONS (Unaudited)
		For the Three Months Ended								For the Nine Months Ended
		2026				2025				2026				2025
Net revenues		$	2,557,295			$	1,687,971			$	7,225,238			$	5,491,944
Cost of services			1,372,254				1,133,430				4,002,639				3,595,352
Gross profit			1,185,041				554,541				3,222,599				1,896,592
Operating expenses:
Salaries and benefits			440,172				336,390				1,204,417				1,169,951
Professional services			175,295				191,726				500,455				580,691
Research and development expenses			46,716				816				100,988				67,701
Selling, general and administrative expenses			222,141				252,384				671,673				828,741
Depreciation			715				5,396				2,510				18,171
Total operating expenses			885,039				786,712				2,480,043				2,665,255
Operating income (loss)			300,002				(232,171)				742,556				(768,663)
Other income (expense):
Interest income			1,008				8,174				54,354				15,892
Interest expense			(1,353)				(1,905)				(6,032)				(8,992)
Total other income (expense)			(345)				6,269				48,322				6,900
Income (loss) before income taxes			299,657				(225,902)				790,878				(761,763)
Benefit of (provision for) income taxes			44,953				-				44,953				-
Net income (loss)		$	344,610			$	(225,902)			$	835,831			$	(761,763)
Weighted average common shares outstanding - basic			14,194,482				11,939,169				13,111,289				11,823,089
Weighted average common shares outstanding - diluted			15,142,247				11,939,169				14,059,054				11,823,089
Net income (loss) per common share - basic and diluted		$	0.02			$	(0.02)			$	0.06			$	(0.06)

SYRA HEALTH CORP. STATEMENTS OF CASH FLOWS (Unaudited)
		For the Nine Months Ended
		September 30,
		2026				2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)		$	835,831			$	(761,763)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation			2,511				18,171
Common stock issued for services			-				2,586
Stock-based compensation			89,685				75,194
Changes in operating assets and liabilities:
Accounts receivable			(599,119)				(245,428)
Other current assets			211,654				279,890
Right-of-use asset			50,511				89,621
Accounts payable			(36,352)				215,723
Accounts payable, related party			53,000				137,764
Deferred revenue			244,638				125,000
Accrued expenses			173,175				(5,691)
Operating lease liability			(50,511)				(89,621)
Net cash provided by operating activities			975,023				(158,554)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment			-				-
Net cash used in investing activities			-				-
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of common stock and exercise of warrants			-				14,800
Repayments on notes payable			(206,343)				(275,106)
Net cash used in financing activities			(206,343)				(260,306)
NET CHANGE IN CASH AND CASH EQUIVALENTS			768,680				(418,860)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD			1,614,733				2,395,405
CASH AND CASH EQUIVALENTS AT END OF PERIOD		$	2,383,413			$	1,976,454
SUPPLEMENTAL INFORMATION:
Interest paid		$	6,032			$	8,992
Income taxes paid		$	-			$	-
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of Class B common stock to Class A common stock		$	2,500			$	2,333
Cashless Exercise of Series B Warrants into Class A common stock		$	11			$	-
Recognition of right-of-use asset and lease liability		$	80,120			$	-
Amendment of right-of-use asset and lease liability		$	-			$	166,119
Prepaid asset financed with note payable		$	269,229			$	311,118

Non-GAAP Financial Measures

In addition to financial results reported in accordance with accounting principles generally accepted in the United States of America ("GAAP"), we have provided the following non-GAAP financial measure in this release and the accompanying tables: adjusted EBITDA. We use this non-GAAP financial measures internally to facilitate period-to-period comparisons and analysis of our operating performance and liquidity and believe it is useful to investors as a supplement to GAAP measures in analyzing, trending, and benchmarking the performance and value of our business. However, this measure is not intended to be a substitute for those reported in accordance with GAAP. These measures may be different from non-GAAP financial measures used by other companies, even when similar terms are used to identify such measures. For reconciliations of historical non-GAAP financial measures to the most comparable financial measures under GAAP, see the table below.

	Nine Months Ended
	September 30, 2026		September 30, 2025
Net Income (Loss)	$                         835,831		$                     (761,763)
Interest expense	6,032		8,992
Depreciation expense	2,510		18,171
Provision for income taxes	(44,953)		-
Earnings before Interest, Taxes Depreciation and Amortization	$                         799,420		$                     (734,600)
	Three Months Ended
	September 30, 2026		September 30, 2025
Net Income (Loss)	$                         344,610		$                     (225,902)
Interest expense	1,353		1,905
Depreciation expense	715		5,396
Provision for income taxes	(44,953)		-
Earnings before Interest, Taxes Depreciation and Amortization	$                         301,725		$                     (218,601)

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy, and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact
Christine Drury
IR/PR Director
Syra Health
[email protected]
463-345-5180

SOURCE Syra Health